Related Experiment Video
Updated: Sep 18, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Closing AI drug-regulatory gaps through harmonized oversight
Surendra Sarsaiya1, Archana Jain2, Jishuang Chen3
1Key Laboratory of Basic Pharmacology and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, 563003, China; Bioresource Institute for Healthy Utilization, Zunyi Medical University, Zunyi, 563003, China.
Abstract:
Artificial intelligence (AI) not only accelerates drug discovery but also creates regulatory gaps-with more than 100 AI-assisted pipelines in trials. Frameworks lack enforceable standards. We propose a risk-tiered framework that distinguishes discovery AI from evidence-generating AI, mandates impact assessments and Investigational New Drug disclosure when AI influences decisions, and transforms guidelines into binding, risk-proportionate regulation.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Clearance: Overview
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including the...
